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Abstract
Background: Although osteoporosis is an easily diagnosed and treatable condition, many individuals remain
untreated. Clinical decision support systems might increase appropriate treatment of osteoporosis. We designed the
Osteoporosis Advisor (OPAD), a computerized tool to support physicians managing osteoporosis at the point-of-
care. The present study compares the treatment recommendations provided by OPAD, an expert physician and the
National Osteoporosis Guideline Group (NOGG).
Methods: We performed a retrospective analysis of 259 patients attending the outpatient osteoporosis clinic at the
University Hospital in Iceland. We entered each patient’s data into the OPAD and recorded the OPAD diagnostic
comments, 10-year risk of major osteoporotic fracture and treatment options. We compared OPAD recommendations
to those given by the osteoporosis specialist, and to those of the NOGG.
Results: Risk estimates made by OPAD were highly correlated with those from FRAX (r = 0.99, 95% CI 0.99, 1.00 without
femoral neck BMD; r = 0.98, 95% CI, 0.97, 0.99 with femoral neck BMD. Reassurance was recommended by the expert,
NOGG and the OPAD in 68, 63 and 52% of cases, respectively. Likewise, intervention was recommended by the expert,
NOGG, and the OPAD in 32, 37 and 48% of cases, respectively. The OPAD demonstrated moderate agreement with the
physician (kappa 0.51, 95% CI 0.41, 0.61) and even higher agreement with NOGG (kappa 0.69, 95% CI 0.60, 0.77).
Conclusion: Primary care physicians can use the OPAD to assess and treat patients’ skeletal health. Recommendations
given by OPAD are consistent with expert opinion and existing guidelines.
Keywords: Clinical decision support system (CDSS), Clinical guidelines, Fracture risk, Osteoporosis, Treatment
recommendations
Background
Osteoporosis is a common disease that causes pro-
gressive deterioration of bone tissue resulting in lower
bone density and an increased risk of an osteoporotic
fracture [1].
Osteoporotic fractures carry a significant risk of mor-
tality and morbidities, forming a growing burden in the
ageing population [2].
Most osteoporotic fractures occur in the non-osteoporotic
range (T-score > − 2.5) [3], emphasizing the influence of
other risk factors on fracture incidence [4]. This has led to
the development of several risk-prediction algorithms whose
roles are to facilitate risk assessment [5]. Currently the best
validated and the most widely used is the FRAX tool intro-
duced in 2008 by the WHO Task Force [4]. The FRAX
algorithm is based on data collected from several large inter-
national cohort studies on risk factors from Europe, North
America, Asia and Australia, and has been validated in
many independent cohorts [6].* Correspondence: haukurtg@icloud.com
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Risk-assessment tools help identify individuals who
need treatment [6], but their usefulness depends on the
clinician’s ability to correctly translate their results into
clinical practice congruent with evidence-based guide-
lines [7, 8]. Osteoporosis is a highly treatable condition
but despite clinical guidelines being widely available [9],
many individuals that are at substantial risk of fracture
still go untreated [10, 11]. Promoting management
guidelines is essential, but that alone is unlikely to solve
this problem, the fact being that only 11% of patients
suffering from a fragility fracture of the hip are started
on bone protective treatment as a secondary prevention
[12]. Additionally, non-adherence to treatment is fre-
quently reported [13]. Consequently, there is obviously
room for improvement in the management of osteopor-
osis, especially at the primary care level [14].
Closing this treatment gap is a priority that involves
improving selection of patients at risk of fracture for
DXA scanning, securing optimal treatment when indi-
cated and providing follow-up that encourages patient
adherence to treatment. Given limited resources allo-
cated to health care it is equally important to avoid per-
forming unnecessary and costly DXA scans among
people with good bone health. Our objective was to
close the gap in osteoporosis care, by identifying individ-
uals at high fracture risk to begin appropriate treatment,
and identifying individuals at low risk of fracture who
would not benefit from DXA scanning. We thus
developed the Osteoporosis Advisor or OPAD (http://
www.expeda.is), a computerized clinical decision support
system to assess and treat osteoporosis in a primary care
setting [15]. The OPAD was developed as a collaboration
between a commercial start-up company (Expeda), The
University of Iceland and Reykjavik University. Although
the source code of the OPAD is currently proprietary,
the OPAD system is openly accessible to all practicing
doctors in Iceland. OPAD provides a patient’s 10-year
fracture probability (with or without BMD values) using
a speedometer-like output that users can easily under-
stand. The OPAD also notes whether a patient would
benefit from BMD measurement by DXA. OPAD
provides patients with lifestyle and treatment recom-
mendations to reduce their fracture risk, incorporating
country-specific guidelines for therapy. Finally, OPAD
provides guidance on whether to refer to an osteoporosis
specialist.
We have previously described the technical design of
the OPAD [15].
The objective of this study was to compare recom-
mendations provided by OPAD both to a osteoporosis
specialist and the current management guidelines from
the NOGG (National Osteoporosis Guideline Group)
[16]. To accomplish this objective, we retrospectively
reviewed the DXA reports and medical records of
patients undergoing routine DXA at one university
setting in 2012.
Methods
We performed a retrospective cohort study, reviewing
the DXA reports and medical records of 308 consecutive
patients undergoing BMD measurement in 2012 at the
University Hospital of Iceland Osteoporosis Clinic. We
excluded individuals < 40 and > 90 years old (n = 13) and
those receiving osteoporosis therapies (n = 36), as FRAX
was not developed to estimate fracture risk in these
individuals.
In the remaining 259 patients, we gathered data from
two major sources:
1) A standardized questionnaire, which all patients
completed prior to DXA scanning. The
questionnaire assessed age, gender, menopausal
status, past DXA scans, hormone replacement
therapy, medication usage (including
corticosteroids), current smoking, family history of
osteoporosis, rheumatoid arthritis, secondary causes
of osteoporosis, previous fracture, calcium and
vitamin D intake and exercise.
2) Detailed DXA reports, stating the height and weight
as measured at the time of BMD testing, BMD
values from the hip and lumbar spine, and written
comments made in a guideline-driven fashion by a
physician with expertise in osteoporosis manage-
ment. Reports contained suggestions for treatment,
suitable follow-up, lifestyle modifications and
additional diagnostic tests, if indicated.
All patients had BMD measured with the same Hologic
QDR 4500A DXA scanner. BMD measurements at the
lumbar spine (L2-L4) and the femoral neck were
performed. BMD was classified according to WHO
definitions (osteopenia, T-score − 1.1 to − 2.4 and osteo-
porosis, T-scores ≤ − 2.5). Patients taking glucocorticoid
therapy (prednisolone > 7.5mg/day) were diagnosed with
glucocorticoid induced osteoporosis if their T-score was
below − 1.5.
Using measured BMD and information gathered from
the questionnaire, we calculated each person’s 10-year
risk of major osteoporotic fracture with FRAX and
OPAD. We accessed the online tool on the FRAX
website (http://www.shef.ac.uk/FRAX/), to determine
10-year fracture risk estimates with, and without, fem-
oral neck BMD. In a similar fashion, we determined
fracture risks using the OPAD with and without femoral
neck BMD. As OPAD takes into account several protect-
ive factors in its risk prediction (estrogen or testosterone
therapy, vitamin D, calcium and exercise), risk estimates
were performed while omitting these protective factors,
Gudmundsson et al. BMC Medical Informatics and Decision Making           (2019) 19:27 Page 2 of 8
thus, using only the risk factors shared by FRAX
and OPAD.
Each case was entered into the OPAD, recommenda-
tions were recorded and then grouped into two categor-
ies: “reassurance” and “intervention indicated”. Likewise,
FRAX scores for each case were evaluated according to
the age variable interventional thresholds proposed by
the National Osteoporosis Guideline Group (NOGG)
[16], and grouped into the two categories (reassurance
and intervention). Finally, the expert physician’s recom-
mendations in each report were grouped into the two
categories of reassurance and therapy.
Statistical methods
We performed statistical analyses using SPSS software
version 22 (Armonk, NY: IBM Corp). We summarized
descriptive data using the mean and standard deviation.
We compared estimates of fracture risk by FRAX and
OPAD using paired t-tests, Pearson correlation coeffi-
cients. We used the Bland-Altman test to assess numeric
agreement within and between the two fracture risk
tools. We assessed inter-rater agreement (reassurance
versus treatment for a given individual) between the
OPAD, FRAX and expert physician using the Kappa test
statistic.
Results
Of the total study population (n = 259), 30 were male
and 229 were female, including 182 post-menopausal
women. Cases’ mean age was 62 ± 10 years old. One
hundred twenty cases had previously undergone BMD
measurement. The majority of cases reported sufficient
intake of calcium, vitamin D and adequate exercise
(Table 1). Sixty-eight individuals (26%) suffered a prior
fragility fracture and 64 individuals (25%) reported a
family history of osteoporosis. Twenty-five cases (10%)
had secondary osteoporosis. We summarize further
characteristics of the study population in Table 1.
One hundred eighty individuals (70%) had osteopenia
and 52 (20%) had osteoporosis based on the BMD values
measured at either the femoral neck or lumbar spine.
T-scores were higher at the lumbar spine, compared to
the femoral neck (− 1.1 vs. − 1.3, p = 0.044). We
summarize BMD data in Table 2.
Fracture risk
Using FRAX, the mean 10-year risk of major osteopor-
otic fracture for the cohort was 15.4 ± 11.3% relying
solely on risk factors and 13.6 ± 9.4% when femoral neck
BMD was included. Using OPAD, fracture risk was
similar (16 ± 11.6% without, and 15.4 ± 11.0% with
femoral neck BMD) (Table 3). Risk estimates made by
Table 1 Demographic variables of the cohort. Values are presented as means ± SD or numbers (%)
Characteristic Women Men Total sample
Population 229 (88%) 30 (12%) 259
Age (years): mean ± SD 61.6 ± 10.2 66,1 ± 11.1 62 ± 10.35
BMI (kg/m2): mean ± SD 25.6 ± 4.6 24.7 ± 2.7 25.5 ± 4.43
Prior scan: n (%) 120 (52%) 10 (33%) 130 (50%)




Receiving hormonal replacement 36 (16%)
Current smoking: n (%) 26 (11%) 5 (17%) 31 (12%)
Glucocorticoids: n (%) 27 (12%) 7 (23%) 34 (13%)
Family history: n (%) 59 (26%) 5 (16%) 64 (25%)
Parent hip-fracture: n (%) 2 (1%) 0 (0%) 2 (1%)
Previous fracture: n (%) 59 (26%) 9 (30%) 68 (26%)
Rheumatoid arthritis: n (%) 19 (8%) 0 (0%) 19 (7%)
Secondary osteoporosis: n (%) 25 (11%) 0 (0%) 25 (10%)
Alcohol users: n (%) 0 (0%) 2 (7%) 2 (1%)
Sufficient calcium intake: n (%) 164 (72%) 23 (77%) 187 (72%)
Sufficient vitamin-D intake: n (%) 174 (76%) 23 (77%) 197 (76%)
Regular exercise: n (%) 114 (50%) 18 (60%) 132 (51%)
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OPAD were highly correlated with those from FRAX
(r = 0.99, 95% CI 0.99, 1.00 without femoral neck
BMD; r = 0.98, 95% CI, 0.97, 0.99 with femoral neck
BMD, Fig. 1).
Bland-Altman analysis revealed that the estimated
probability of fracture using FRAX with BMD was lower
by 1.8% (95% CI, − 2.5, − 1.1%, p < 0.001), compared to
the estimated fracture risk using FRAX without hip
BMD values (Fig. 2). OPAD estimates of fracture risk
were similar, whether determined with or without hip
BMD (p = 0.098). Without BMD values, OPAD overesti-
mated fracture risk compared to FRAX (bias 0.63, 95%
CI 0.5, 0.8%, p < 0.001). Likewise, when using hip BMD
values to estimate fracture risk, the OPAD overestimated
risk compared to FRAX (bias 1.8, 95% CI -1.5%, 2.1, p <
0.001). However, while the OPAD fracture risk estimates
were significantly higher than FRAX based on statistical
tests, the numeric differences in fracture risk using the
two tools were very small.
The physician, NOGG and OPAD recommended
reassurance in 68, 63 and 52% of 259 cases, respectively.
Conversely, the physician, NOGG and OPAD recom-
mended intervention in 32, 37 and 48% of cases, respect-
ively (Fig. 3). We used kappa test statistics to assess
within-subject agreement to reassure or treat, using the
OPAD or FRAX with NOGG directed therapy. The OPAD
demonstrated moderate agreement with the physician
(kappa 0.51, 95% CI 0.41, 0.61) and even higher agreement
with NOGG (kappa 0.69, 95% CI 0.60, 0.77). The
physician was in moderate agreement with NOGG (kappa
0.53 (95% CL 0.415, 0.629) (Table 4 and Fig. 4).
Discussion
Osteoporosis is a common disease that remains asymp-
tomatic until a fragility fracture occurs; representing a
silent epidemic disorder. The only way to diagnose
osteoporosis prior to fracture is by measuring BMD [17].
It is of importance to identify those who are at high risk
of fragility fractures and thus could benefit from DXA
evaluation and treatment intervention [18]. Several
interest organizations including the National Osteopor-
osis Foundation (NOF) recommend BMD screening for
women starting at the age of 65 and for men starting at
age 70 [19]. Despite good access to DXA, effective treat-
ments and widely published treatment guidelines,
patients remain untreated, even after suffering hip frac-
tures [10]. Therefore, we developed a user-friendly clin-
ical tool to support primary care providers in decisions
to screen for and treat osteoporosis. We compared the
performance of the OPAD to that of FRAX, the most
widely used and best-validated of several fracture risk
calculators [20]. In our study, the risk evaluations made
by OPAD were highly correlated with calculations made
by FRAX. Correlation between FRAX and OPAD
remained high even after additional protective factors
(hormonal therapy, vitamin D, calcium intake and exer-
cise) where included in the risk calculations made by
OPAD (data not shown).
Although low BMD is strongly associated with in-
creased fracture risk, it is essential to incorporate other
risk factors to sufficiently evaluate and select at-risk
patients for bone protective treatment [21]. The FRAX
risk assessment tool is intended to aid the clinician in
the decision to initiate preventive treatment by providing
the patient’s ten-year risk of an osteoporotic fracture.
However, there are several limitations of FRAX that have
already been discussed [22, 23]. Furthermore, the frac-
ture risk given by FRAX still needs to be interpreted in
accordance with the terms in the current management
guidelines. Although those guidelines are readily avail-
able, too many patients-at-risk are receiving sub-optimal
treatment [24]. Consequently, there is obviously room
for improvement in the management of osteoporosis,
especially at the primary care level [14].
The agreement of the recommendations given by the
OPAD to those given by the osteoporosis specialist and
NOGG guidelines are of importance. Our study shows
that recommendations made by OPAD are in good
agreement to specialist advice and even stronger agree-
ment to the NOGG intervention thresholds. With zero
Table 2 Bone mineral density and osteoporosis (T-value ≤ −2.5)
or osteopenia (T-value −1 - -2.5) according to WHO definitions
DXA site Women (n = 229) Men (n = 30) Total (n = 259)
Femoral neck
Osteoporosis: n (%) 25 (11%) 2 (7%) 27 (10%)
Osteopenia: n (%) 120 (52%) 18 (60%) 138 (53%)
T-score mean ± SD −1.3 ± 1.0 −1.3 ± 0.7 -1.3 ± 0.9
Lumbar spine
Osteoporosis: n (%) 31 (14%) 6 (20%) 37 (14%)
Osteopenia: n (%) 92 (40%) 17 (57%) 109 (42%)
T score mean ± SD −1.1 ± 1.5 − 1.4 ± 1.6 −1.1 ± 1.5
Neck or spine
Osteoporosis: n (%) 45 (20%) 7 (23%) 52 (20%)
Osteopenia: n (%) 155 (68%) 25 (83%) 180 (70%)
Table 3 Estimates of the 10-year risk (%) of major osteoporotic
fracture as calculated by FRAX and OPAD
Risk estimation tool Women (n = 229) Men (n = 30) Total (n = 259)
FRAX mean (SD)
With BMD (%) 14 ± 10% 11 ± 5% 14 ± 9%
Without BMD (%) 16 ± 12% 11 ± 5% 15 ± 11%
OPAD mean (SD)
With BMD (%) 16 ± 12% 12 ± 5% 15 ± 11%
Without BMD (%) 17 ± 12% 12 ± 6% 16 ± 12%
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Fig. 1 Ten-year risk estimates (without BMD values) from OPAD (x-axis) compared to FRAX (y-axis)
Fig. 2 Bland-Altman plots comparing 10-year fracture risk estimates of OPAD and FRAX with and without BMD values
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patients being recommended “reassurance” in discord-
ance to either a specialist or NOGG, our study shows
the OPAD system does not overlook individuals who
need bone protective treatment. When OPAD recom-
mended active treatment intervention, the majority of
cases were in agreement to both the specialist and
NOGG but 16% (n = 23) were discordant, demonstrating
a slightly more aggressive stance for treatment. In the
most of those cases (n = 23, 74%), the OPAD system had
made the recommendation to seek expert advice. To
facilitate comparison those recommendations where
classified as an intervention, thus accounting for some
cases of discrepancy between OPAD and the expert
physician. The rest of the cases (n = 6) are explained by
OPAD’s slight overestimation in its risk estimations
compared to FRAX as revealed by Bland-Altman’s ana-
lysis. Several other reasons might explain why OPAD
and the clinician disagreed, e.g. additional clinical infor-
mation that the specialist had access to but was not
included in OPAD.
More important is the fact that OPAD not only gives
the fracture risk, but also recommend clinical decisions
based on guidelines [15]. Thus, health care professionals
do not need to know the guidelines in order to use
OPAD. The software design of OPAD allows it to be ef-
fortlessly integrated in to different EMR (Electronic
Medical Record) systems so to fit easily in to existing
workflow of health care providers, further enabling it’s
use at the point of care. Furthermore, with a systematic
approach using a CDSS (Clinical Decision Support
System) such as OPAD in the osteoporosis care, we
might reduce the cost and improve the utilization of
diagnostic resources. Further health economic studies
on this issue are of interest.
It is important to note that the OPAD system is not
solely a risk calculator like FRAX, but a fully featured
CDSS that evaluates patient risk factors and BMD values
to provide the clinician with treatment recommendation,
and advice on proper follow-up. OPAD also highlights
primary prevention and selects individuals for further
work-up, such as BMD measurement or referral to an
osteoporosis specialist [15]. In the present study, the
OPAD tool was tested on an Icelandic population, but
using different epidemiological data, OPAD is able to
run in up to ten different national specific datasets [15].
Our study has both strengths and limitations. The
strength of this study is that it is based on a real-life
data, gathered from a BMD centre that does not require
a doctor’s referral for post and peri-menopausal females
and should therefore be a better representation of a
typical primary care population compared to a strict ter-
tiary referral centre. Furthermore, the osteoporosis spe-
cialist who analysed the DXAs was unaware of the
present study, minimizing potential interpretation or
performance bias. In addition, the risk evaluation and
recommendations given by the OPAD are concordant
with those from FRAX and an osteology specialist. Thus,
the data set and results are of interest for general prac-
tice. The limitations of this study are its retrospective
Fig. 3 Frequency of recommendations made by OPAD, physician and NOGG
Table 4 Inter-rater agreement using percentage and kappa
statistics
OPAD Physician NOGG
Agreement (%) 76% 85%
Kappa (95% CI) 0.51 (0.41–0.61) 0.69 (0.60–0.77)
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design, small sample size, non-random sampling of a
racially homogenous study population and that it was
conducted at a single academic centre.
The OPAD is under active development and adapts to
ever changing management guidelines. Further patient
factors may be incorporated into the risk assessment
model of OPAD, such as loss of height, history of falls
and it is even possible to add individual genotypes to im-
prove the fracture risk estimation. We believe the posi-
tive observations made from this limited retrospective
study warrant the undertaking of a larger multi-centred
prospective validation study in a primary care setting.
Conclusion
We conclude that fracture risk estimations made by the
OPAD system are equivalent to risk calculations made
by FRAX. Treatment recommendations by OPAD are
accurate and consistent with NOGG guidelines and
those given by a practicing specialist. With the use of a
clinical decision aid such as OPAD, we offer a new
approach to reduce gaps in screening and treatment for
older patients, many of whom suffer from osteoporosis.
Our tool is novel as it provides an output that is user
friendly and easily understood by both patients and
primary care providers, regardless of their knowledge of
treatment guidelines.
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